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Vaccines are a cornerstone of public health, and one of the
most cost-effective means of preventing several infectious
diseases ranging from acute (e.g. measles and mumps) to
chronic diseases (e.g. chronic hepatitis B), and some
virus-related human cancers (e.g. liver and cervical cancer).
As part of its multifaceted approach to infections, the
European Society of Clinical Microbiology and Infectious
Diseases (ESCMID) strives to promote vaccination and
worries that the current lack of knowledge among the lay
public and healthcare providers may seriously undermine the
efﬁcacy of current and future vaccine campaigns. To achieve
this, ESCMID organised the ﬁrst vaccine-related conference,
The Impact of Vaccines on Public Health, in Prague, the Czech
Republic in March 2011. The conference brought together
leading experts from all over the world to debate the
many-sided correlations between vaccines, medicine and
society at the dawn of the third millennium. The target
audience consisted of specialists in infectious diseases, clinical
microbiology, paediatrics, hygiene, public health, vaccinology
and other related disciplines, as well as physicians in training.
As the result of the conference Clinical Microbiology and
Infection (CMI) published a 16-paper special issue The Impact of
Vaccines on Public Health in October 2012 (Volume 18,
Supplement 5, Guest Editor: Mical Paul).
The success of the ﬁrst conference encouraged organisation
of the second ESCMID vaccine-related conference, which was
again held in Prague in March 2013. This was an even more
successful conference which attracted more than 400 dele-
gates. As the result of this conference we have produced this
special issue of CMI which contains 17 papers covering a wide
range of topics. The topics range from timely reviews of
available vaccines and vaccination strategies to phase 1 results
of candidate DNA vaccines.
Both ESCMID vaccine conferences fostered a wide-ranging
debate inside the society that led to the creation of an ofﬁcial
ESCMID Vaccine Study Group (EVASG). The inauguration
meeting was held at ECCMID 2013 in Berlin, Germany.
Although a number of other professional societies are
dedicated to the ﬁeld of vaccination, ESCMID strongly believes
that our new study group can attract new professionals and
that only common collaborative work can lead to success.
Anyone who would like to join EVASG can apply to become a
member at https://www.escmid.org/research_projects/study_-
groups/vaccines/. Membership is free for all ESCMID members
in good standing.
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